1. 214P Location matters: Oral cancer cells at the tumor invasive border that express GARP exclude immune cells. (December 2022) Authors: van de Ven, R.; Wondergem, N.E.; Ganzevles, S.H.; Leemans, C.R.; Brakenhoff, R.H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O5.3 The tumor immune microenvironment of HPV-negative and HPV-positive oropharynx squamous cell carcinomas. (November 2022) Authors: Muijlwijk, T.; Nijenhuis, D.; Ganzevles, S.; Leemans, R.; Brakenhoff, R.; van de Ven, R. Journal: Oral oncology Issue: Volume 134(2022)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Oncolytic adenovirus ORCA‐010 increases the type 1 T cell stimulatory capacity of melanoma‐conditioned dendritic cells. (6th May 2020) Authors: López González, M.; van de Ven, R.; de Haan, H.; van Eck van der Sluijs, J.; Dong, W.; van Beusechem, V. W.; de Gruijl, T. D. Journal: Clinical and experimental immunology Issue: Volume 201:Number 2(2020) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-186 Neoadjuvant immune checkpoint inhibition in stage III/IV oral cancer patients: the NeoNivo trial. (July 2021) Authors: Wondergem, N.E.; Miedema, I.H.C.; van de Ven, R.; Brakenhoff, R.H.; Menke-van der Houven van Oordt, C.W.; Leemans, C.R. Journal: Oral oncology Issue: Volume 118(2021)Supplement Page Start: 4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗